Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Weekly pill could cut migraine days in half

NCT ID NCT07072910

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests whether a weekly dose of cabergoline, a drug that affects dopamine, can reduce the number of migraine days in adults with episodic migraine (4-14 migraine days per month). 150 participants will be randomly assigned to receive cabergoline (0.5 mg or 1.0 mg) or a placebo once a week for 12 weeks, followed by an open-label phase where everyone gets cabergoline. The study tracks migraine frequency, severity, and medication use through daily diaries and questionnaires.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Cabergoline (Dostinex), a dopamine receptor agonist taken as a weekly oral tablet
What this could lead to
If it works, this could provide a new, once-weekly preventive option for people with episodic migraine, reducing the number of migraine days per month.
What could go wrong
This is an early phase 2 trial with only 150 participants, so results may not apply to everyone. Cabergoline can cause side effects like nausea, dizziness, or heart valve issues, and it may not prove more effective than placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 150 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2025

Expected to finish

Sep 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥18 years * Episodic migraine according to ICHD-3 criteria * 4-14 monthly migraine days (MMD) in the last 3 months prior to inclusion * Stable acute migraine medication use for at least 3 months prior to inclusion * Written informed consent Exclusion Criteria: * \< 4 MMD or ≥ 15 MMD during the baseline period * Chronic migraine (≥15 headache days per month) * Trigeminal autonomic cephalalgias and neuralgias * Secondary headache conditions * Other common primary headache types (e.g. tension-type headache) if attacks are frequent (present on an average of \>1 day/month and \>12 days/year) * Presumed medication-overuse headache * Recent changes in preventive migraine treatment (≥3 months prior to study inclusion) * History of pulmonary, retroperitoneal, or pericardial disorders, including heart valve disease * Severe untreated hypertension * Use of drugs with dopamine antagonistic or agonistic properties * Psychiatric disorders requiring pharmacological treatment * Women of child-bearing potential (i.e. not chemically or surgically sterilized, or not postmeno-pausal) and male participants with partners of child-bearing potential, who are unwilling to use a medically accepted method of contraception, considered reliable by the investigator, from signing of informed consent and throughout the study * Women who have a positive pregnancy test at randomization * Women who are breast-feeding * Allergy or hypersensitivity to cabergoline or similar compounds * Concurrent participation in another clinical trial that, in the judgement of the investigator, may interfere with the conduct or outcomes of the present study * Inability of the subject, in the opinion of the investigator, to understand and/or comply with study medications or procedures, or any conditions that, in the opinion of the investigator, may render the subject unable to complete the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Migraine are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Aarhus University Hospital

    RECRUITING

    Aarhus N, 8200, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.